ATE479763T1 - Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen - Google Patents
Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellenInfo
- Publication number
- ATE479763T1 ATE479763T1 AT04751183T AT04751183T ATE479763T1 AT E479763 T1 ATE479763 T1 AT E479763T1 AT 04751183 T AT04751183 T AT 04751183T AT 04751183 T AT04751183 T AT 04751183T AT E479763 T1 ATE479763 T1 AT E479763T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- compositions
- cells
- transport
- acid analogue
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 239000003124 biologic agent Substances 0.000 abstract 2
- 108010082406 peptide permease Proteins 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46670303P | 2003-04-29 | 2003-04-29 | |
PCT/US2004/013660 WO2004097017A2 (en) | 2003-04-29 | 2004-04-29 | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE479763T1 true ATE479763T1 (de) | 2010-09-15 |
Family
ID=33418412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04751183T ATE479763T1 (de) | 2003-04-29 | 2004-04-29 | Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen |
Country Status (9)
Country | Link |
---|---|
US (4) | US7468418B2 (de) |
EP (2) | EP1629105B1 (de) |
AT (1) | ATE479763T1 (de) |
AU (2) | AU2004235396B2 (de) |
CA (1) | CA2523672C (de) |
DE (1) | DE602004028930D1 (de) |
DK (1) | DK2351844T3 (de) |
ES (2) | ES2500921T3 (de) |
WO (1) | WO2004097017A2 (de) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
ES2500921T3 (es) | 2003-04-29 | 2014-10-01 | Sarepta Therapeutics, Inc. | Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células |
US20050203041A1 (en) * | 2003-09-23 | 2005-09-15 | Mourich Dan V. | Antisense compound and method for selectively killing activated T cells |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
US20050234002A1 (en) * | 2004-01-23 | 2005-10-20 | Mourich Dan V | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
SI2206781T1 (sl) | 2004-06-28 | 2016-05-31 | The University Of Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
PT1766012E (pt) | 2004-07-02 | 2011-09-05 | Avi Biopharma Inc | Método e composto antisense antibacteriano |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
EP1656951A1 (de) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Konjugate mit verbesserter Zellaufnahme |
US20100256041A1 (en) * | 2004-11-12 | 2010-10-07 | Christophe Bonny | Conjugate Molecule Compounds With Enhanced Cell Uptake Activity |
EP1855694B1 (de) * | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense-zusammensetzung zur behandlung von muskelatrophie |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
AU2006267051B2 (en) * | 2005-07-13 | 2013-03-07 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
CA2621964A1 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
WO2007031098A1 (en) * | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US8080517B2 (en) * | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
EP2109363A4 (de) * | 2006-12-29 | 2014-07-09 | Revance Therapeutics Inc | Transportmoleküle mit umkehrsequenz-hiv-tat-polypeptiden |
US8067532B2 (en) * | 2007-01-19 | 2011-11-29 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
JP5864100B2 (ja) * | 2007-06-29 | 2016-02-17 | サレプタ セラピューティクス インコーポレイテッド | 組織特異的ペプチドコンジュゲートおよび方法 |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
US7989608B2 (en) * | 2007-12-28 | 2011-08-02 | Avi Biopharma Inc. | Immunomodulatory agents and methods of use |
EP2119783A1 (de) * | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2010048586A1 (en) | 2008-10-24 | 2010-04-29 | Avi Biopharma, Inc. | Multiple exon skipping compositions for dmd |
CA2746508A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2010099510A2 (en) * | 2009-02-27 | 2010-09-02 | The Administrators Of The Tulane Educational Fund | Amino acid-based compounds, their methods of use, and methods of screening |
WO2010120262A1 (en) * | 2009-04-14 | 2010-10-21 | Smith Holdings, Llc | Methods and compositions for the treatment of medical conditions involving cellular programming |
WO2010121125A1 (en) | 2009-04-17 | 2010-10-21 | Wake Forest University Health Sciences | Il-13 receptor binding peptides |
US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
AU2010286368B2 (en) | 2009-08-31 | 2015-09-03 | Gen-Probe Incorporated | Dengue virus assay |
KR102487132B1 (ko) | 2009-11-12 | 2023-01-10 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
CN102712928B (zh) | 2009-11-13 | 2017-08-04 | 萨雷普塔治疗公司 | 反义抗病毒化合物及治疗流感病毒感染的方法 |
US20120309684A1 (en) * | 2009-11-30 | 2012-12-06 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
JP5457813B2 (ja) * | 2009-12-16 | 2014-04-02 | ルネサスエレクトロニクス株式会社 | Adpll回路、半導体装置及び携帯情報機器 |
WO2011084694A1 (en) | 2009-12-17 | 2011-07-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Stabilized stat3 decoy oligonucleotides and uses therefor |
US9068185B2 (en) * | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
ES2816898T3 (es) | 2010-05-13 | 2021-04-06 | Sarepta Therapeutics Inc | Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23 |
KR102095478B1 (ko) | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
CA2834128A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
WO2013033407A2 (en) | 2011-08-30 | 2013-03-07 | The Regents Of The University Of California | Identification of small molecules that enhance therapeutic exon skipping |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
EP2780299A4 (de) | 2011-11-18 | 2015-04-22 | Sarepta Therapeutics Inc | Funktionsmodifizierte oligonukleotide und untereinheiten davon |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
JP6542662B2 (ja) | 2012-03-20 | 2019-07-10 | サレプタ セラピューティクス, インコーポレイテッド | オリゴヌクレオチドアナログのボロン酸結合体 |
WO2014011177A1 (en) * | 2012-07-12 | 2014-01-16 | Smith Holdings, Llc | Antisense p53 phosphorodiamidate morpholino composititons, methods and indications |
BR122020016865B1 (pt) | 2013-03-14 | 2022-12-27 | Sarepta Therapeutics, Inc. | Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd) |
CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
US9885040B2 (en) * | 2013-04-12 | 2018-02-06 | The Curators Of The University Of Missouri | SMN2 element 1 antisense compositions and methods and uses thereof |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
CN105307670A (zh) | 2013-06-26 | 2016-02-03 | 埃克西金炎症有限公司 | Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途 |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
EP3620178A3 (de) | 2014-05-16 | 2020-07-22 | Oregon State University | Antibakterielle antisense-verbindungen und verfahren |
EP3569252B1 (de) | 2014-05-19 | 2021-12-15 | Oregon State University | Antibakterielle antisense-verbindungen und verfahren |
CA2949104C (en) | 2014-05-23 | 2023-09-26 | Genzyme Corporation | Multiple oligonucleotide moieties on peptide carrier |
JP6994941B2 (ja) | 2014-12-31 | 2022-02-04 | オレゴン ステート ユニバーシティ | アンチセンス抗細菌性化合物および方法 |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
EP3302489A4 (de) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten |
EP3858993A1 (de) * | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen |
US10907158B2 (en) | 2015-12-23 | 2021-02-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
WO2017112888A1 (en) | 2015-12-23 | 2017-06-29 | David Greenberg | Antisense antibacterial compounds and methods |
SG11201808964PA (en) | 2016-04-18 | 2018-11-29 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
NZ747685A (en) | 2016-04-29 | 2023-05-26 | Sarepta Therapeutics Inc | Oligonucleotide analogues targeting human lmna |
BR112019012664A2 (pt) | 2016-12-19 | 2020-01-21 | Sarepta Therapeutics Inc | conjugados de oligômero de salto de éxon para distrofia muscular |
MD3554553T2 (ro) | 2016-12-19 | 2022-10-31 | Sarepta Therapeutics Inc | Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară |
CN206351680U (zh) * | 2017-01-04 | 2017-07-25 | 上海蔚来汽车有限公司 | 自适应调整位置的加解锁夹具 |
TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Nrf2路徑的新穎化合物 |
JP7441455B2 (ja) | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
US20210145852A1 (en) | 2017-09-28 | 2021-05-20 | Sarepta Therapeutics, Inc. | Combination Therapies for Treating Muscular Dystrophy |
US20200254002A1 (en) | 2017-09-28 | 2020-08-13 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
EP3806868A4 (de) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomere für muskeldystrophie |
TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
CA3122200A1 (en) * | 2018-12-07 | 2020-06-11 | Oxford University Innovation Limited | Linkers |
EA202191601A1 (ru) | 2018-12-13 | 2022-01-19 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
US20220193246A1 (en) | 2019-04-18 | 2022-06-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
WO2021042039A1 (en) * | 2019-08-29 | 2021-03-04 | Ajk Pharmaceutical Llc | Synthetic antimicrobial peptides |
US20230020092A1 (en) * | 2019-12-19 | 2023-01-19 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
EP4267191A1 (de) | 2020-12-23 | 2023-11-01 | Sarepta Therapeutics, Inc. | Zusammensetzungen mit exon-skipping-oligonukleotidkonjugaten zur behandlung von muskeldystrophie |
EP4330395A1 (de) | 2021-04-30 | 2024-03-06 | Sarepta Therapeutics, Inc. | Behandlungsverfahren für muskeldystrophie |
WO2023034515A2 (en) | 2021-09-03 | 2023-03-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
CA3233242A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
DE3687030T2 (de) | 1985-03-15 | 1993-03-11 | James Summerton | Stereoregulare polynukleotiden bindende polymere. |
US5525465A (en) * | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5378841A (en) | 1989-12-20 | 1995-01-03 | Antivirals Inc. | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
CA2063529A1 (en) | 1991-03-22 | 1992-09-23 | Katsuro Tachibana | Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same |
GB9209032D0 (en) * | 1992-04-25 | 1992-06-10 | Ciba Geigy Ag | New peptide derivatives |
DE656950T1 (de) | 1992-08-21 | 1996-03-14 | Biogen Inc | Tat-derivate transport polypeptide. |
KR100316205B1 (ko) * | 1993-01-07 | 2002-04-24 | 아브람 엠. 골드핑거 | 평활근세포의증식을조절하기위한c-myc의안티센스억제 |
GB9318288D0 (en) | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
WO1995007072A2 (de) | 1993-09-09 | 1995-03-16 | Schering Aktiengesellschaft | Wirkstoffe und gas enthaltende mikropartikel |
GB9402867D0 (en) | 1994-02-15 | 1994-04-06 | Nycomed Imaging As | Improvements in or relating to contrast agents |
GB9417941D0 (en) | 1994-09-06 | 1994-10-26 | Nycomed Imaging As | Improvements in or relating to contrast agents |
US5648098A (en) | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
CN1263473A (zh) | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
WO1999005302A1 (en) | 1997-07-24 | 1999-02-04 | The Perkin-Elmer Corporation | Conjugates of transporter peptides and nucleic acid analogs, and their use |
CA2337361C (en) | 1998-07-13 | 2010-11-16 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
EP1109821A4 (de) * | 1998-08-25 | 2002-04-03 | Human Genome Sciences Inc | 49 human-sekretierte proteine |
JP2002535015A (ja) | 1999-01-29 | 2002-10-22 | エイブイアイ バイオファーマ, インコーポレイテッド | 標的rnaを検出するための非侵襲性方法 |
EP1173614A4 (de) * | 1999-04-08 | 2003-10-29 | Oasis Biosciences Inc | Antisense oligonukleotide enthaltend universelle und/oder degenerierte basen |
DE60039601D1 (de) | 1999-05-24 | 2008-09-04 | Avi Biopharma Inc | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit |
US6303573B1 (en) * | 1999-06-07 | 2001-10-16 | The Burnham Institute | Heart homing peptides and methods of using same |
US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
MXPA02001857A (es) * | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
CA2386192A1 (en) | 1999-10-07 | 2001-04-12 | Avi Biopharma, Inc. | C-myc antisense-treated hematopoietic stem cell composition and method |
ATE393221T1 (de) | 1999-11-29 | 2008-05-15 | Avi Biopharma Inc | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
US7049431B2 (en) | 2000-01-04 | 2006-05-23 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US20040170955A1 (en) * | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
US6559279B1 (en) * | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
EP1191097A1 (de) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induktion von "exon-skipping" in eukaryotischen Zellen |
AU2002225714A1 (en) | 2000-11-10 | 2002-05-21 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
EP1364201A4 (de) * | 2001-02-06 | 2005-01-05 | Univ Auburn | Liganden-sensorvorrichtungen und verwendungen davon |
US20030031655A1 (en) * | 2001-02-08 | 2003-02-13 | Sequitur, Inc. | Methods of light activated release of ligands from endosomes |
JP2005508832A (ja) * | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
US7456146B2 (en) * | 2001-05-09 | 2008-11-25 | Ghc Research Development Corporation | Lytic peptide prodrugs |
EP1399462A4 (de) * | 2001-05-17 | 2008-03-05 | Avi Biopharma Inc | Kombinierter ansatz zur behandlung von krebs mit einem c-myc-antisense-oligomer |
AT413185B (de) | 2001-05-17 | 2005-12-15 | Blum Gmbh Julius | Möbelschublade |
JP3735292B2 (ja) * | 2001-07-26 | 2006-01-18 | 三菱重工業株式会社 | ダイエット効果のある健康食品および製剤 |
US6645974B2 (en) * | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
US20090075377A1 (en) * | 2001-08-03 | 2009-03-19 | Arbor Vita Corporation | Molecular interactions in cells |
US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
MXPA04005611A (es) * | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
WO2004084805A2 (en) * | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
ES2500921T3 (es) | 2003-04-29 | 2014-10-01 | Sarepta Therapeutics, Inc. | Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células |
KR100835786B1 (ko) | 2003-07-08 | 2008-06-09 | 제넨테크, 인크. | Il-17a/f 이종 폴리펩티드 및 그의 치료 용도 |
EP2251352A1 (de) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogene Präparate von IL-28 und IL-29 |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20050203041A1 (en) | 2003-09-23 | 2005-09-15 | Mourich Dan V. | Antisense compound and method for selectively killing activated T cells |
US7786151B2 (en) * | 2004-01-09 | 2010-08-31 | Kinopharma, Inc. | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction |
US20050234002A1 (en) * | 2004-01-23 | 2005-10-20 | Mourich Dan V | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
WO2005077333A2 (en) * | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Gel-based delivery of recombinant adeno-associated virus vectors |
US7402574B2 (en) | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
MXPA06012605A (es) | 2004-05-04 | 2006-12-15 | Nastech Pharm Co | Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas. |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
WO2005117992A2 (en) * | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Controlled delivery of therapeutic compounds |
SI2206781T1 (sl) | 2004-06-28 | 2016-05-31 | The University Of Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe |
EP1789553B1 (de) * | 2004-06-30 | 2014-03-26 | Alnylam Pharmaceuticals Inc. | Oligonukleotide mit einer nicht-phosphat-rückgratbindung |
EP2801366A3 (de) * | 2004-09-02 | 2015-04-29 | Cognosci, Inc. | Verbesserte ApoE-Analoga und Verwendungsverfahren dafür |
WO2006031996A2 (en) * | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
EP1855694B1 (de) * | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense-zusammensetzung zur behandlung von muskelatrophie |
RU2007129263A (ru) | 2005-02-14 | 2009-03-20 | Вайет (Us) | Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение |
CA2605931A1 (en) * | 2005-04-26 | 2006-11-02 | Karyon-Ctt Ltd | Diagnostic and therapeutic agents |
WO2008005002A1 (en) | 2006-06-30 | 2008-01-10 | Oligos Ets. Inc. | Compositions and methods for the treatment of muscle wasting |
US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
AU2006267051B2 (en) | 2005-07-13 | 2013-03-07 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
CA2621964A1 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
CA2624081C (en) * | 2005-09-29 | 2014-09-16 | Medimmune, Inc. | Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
EP1954836B1 (de) | 2005-11-08 | 2014-01-08 | Sarepta Therapeutics, Inc. | Verbindung zur Immununterdrückung und Behandlungsverfahren |
US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2007103529A2 (en) | 2006-03-07 | 2007-09-13 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
EP2735568B8 (de) * | 2006-05-10 | 2017-09-27 | Sarepta Therapeutics, Inc. | Oligonucleotid-analoge mit kationischen Zwischenuntereinheitsverknüpfungen |
WO2008018795A1 (en) * | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
US20080267978A1 (en) * | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
AU2007297535C1 (en) * | 2006-09-21 | 2017-11-23 | University Of Florida Research Foundation, Inc. | Compositions and methods related to protein displacement therapy for myotonic distrophy |
FR2908999B1 (fr) * | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
EP1938802A1 (de) | 2006-12-22 | 2008-07-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | RNA-Interferenz (RNAi)-Moleküle gezielt auf proinflammtorische Cytokine |
JP5864100B2 (ja) * | 2007-06-29 | 2016-02-17 | サレプタ セラピューティクス インコーポレイテッド | 組織特異的ペプチドコンジュゲートおよび方法 |
US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
WO2009026412A1 (en) | 2007-08-21 | 2009-02-26 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
US20110039785A1 (en) | 2007-12-20 | 2011-02-17 | Angiochem Inc. | Polypeptide-nucleic acid conjugates and uses thereof |
US7989608B2 (en) * | 2007-12-28 | 2011-08-02 | Avi Biopharma Inc. | Immunomodulatory agents and methods of use |
WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
WO2010048586A1 (en) | 2008-10-24 | 2010-04-29 | Avi Biopharma, Inc. | Multiple exon skipping compositions for dmd |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
CA2746508A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
WO2010101663A2 (en) | 2009-03-06 | 2010-09-10 | Mount Sinai School Of Medicine Of New York University | Live attenuated influenza virus vaccines comprising microrna response elements |
US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
WO2011049603A1 (en) | 2009-10-22 | 2011-04-28 | Dana-Farber Cancer Institute, Inc. | Biomarkers to identify hiv-specific t-cell subsets |
CN102712928B (zh) | 2009-11-13 | 2017-08-04 | 萨雷普塔治疗公司 | 反义抗病毒化合物及治疗流感病毒感染的方法 |
US9068185B2 (en) | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
ES2816898T3 (es) * | 2010-05-13 | 2021-04-06 | Sarepta Therapeutics Inc | Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23 |
US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2004
- 2004-04-29 ES ES10174646.9T patent/ES2500921T3/es not_active Expired - Lifetime
- 2004-04-29 DE DE602004028930T patent/DE602004028930D1/de not_active Expired - Lifetime
- 2004-04-29 ES ES04751183T patent/ES2351976T3/es not_active Expired - Lifetime
- 2004-04-29 US US10/836,804 patent/US7468418B2/en active Active
- 2004-04-29 CA CA2523672A patent/CA2523672C/en not_active Expired - Fee Related
- 2004-04-29 WO PCT/US2004/013660 patent/WO2004097017A2/en active Application Filing
- 2004-04-29 DK DK10174646.9T patent/DK2351844T3/da active
- 2004-04-29 AT AT04751183T patent/ATE479763T1/de not_active IP Right Cessation
- 2004-04-29 AU AU2004235396A patent/AU2004235396B2/en not_active Ceased
- 2004-04-29 EP EP04751183A patent/EP1629105B1/de not_active Expired - Lifetime
- 2004-04-29 EP EP10174646.9A patent/EP2351844B1/de not_active Expired - Lifetime
-
2008
- 2008-11-05 US US12/265,499 patent/US9572899B2/en active Active
-
2011
- 2011-02-18 AU AU2011200720A patent/AU2011200720B2/en not_active Ceased
-
2017
- 2017-01-10 US US15/402,449 patent/US10300149B2/en not_active Expired - Lifetime
-
2019
- 2019-04-09 US US16/379,046 patent/US10905782B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2011200720B2 (en) | 2012-11-08 |
US9572899B2 (en) | 2017-02-21 |
US20090082547A1 (en) | 2009-03-26 |
ES2351976T3 (es) | 2011-02-14 |
EP2351844B1 (de) | 2014-06-11 |
DK2351844T3 (da) | 2014-09-22 |
US7468418B2 (en) | 2008-12-23 |
WO2004097017A3 (en) | 2005-04-07 |
WO2004097017A2 (en) | 2004-11-11 |
CA2523672C (en) | 2012-07-17 |
US10300149B2 (en) | 2019-05-28 |
ES2500921T3 (es) | 2014-10-01 |
US20200016280A1 (en) | 2020-01-16 |
US20170368203A1 (en) | 2017-12-28 |
AU2004235396A1 (en) | 2004-11-11 |
AU2004235396B2 (en) | 2010-11-25 |
US20040265879A1 (en) | 2004-12-30 |
CA2523672A1 (en) | 2004-11-11 |
AU2011200720A1 (en) | 2011-03-10 |
DE602004028930D1 (de) | 2010-10-14 |
EP1629105A2 (de) | 2006-03-01 |
EP2351844A1 (de) | 2011-08-03 |
US10905782B2 (en) | 2021-02-02 |
EP1629105B1 (de) | 2010-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE479763T1 (de) | Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen | |
DE69531332D1 (de) | Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert | |
AU9078401A (en) | Antimicrobial peptides and methods of use | |
RU2007106075A (ru) | Композиции и способы применения ангиопоэтинподобного белка 4 | |
ATE294504T1 (de) | Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen | |
EA201071323A1 (ru) | Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения | |
ATE432291T1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
ATE514777T1 (de) | Verbindungen und verfahren zur modulation von genexpression | |
DE60125381D1 (de) | Zusammensetzungen und verfahren mit analogen von g-csf | |
NO984415L (no) | Peptider med antiproliferative egenskaper | |
IL206157A (en) | Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein | |
CY1109631T1 (el) | Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ | |
ATE500266T1 (de) | Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine | |
CA2265444A1 (en) | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods | |
Novopashina et al. | Sequence‐specific conjugates of oligo (2′‐O‐methylribonucleotides) and hairpin oligocarboxamide minor‐groove binders: Design, synthesis, and binding studies with double‐stranded DNA | |
Petersen et al. | Synthesis and in Vitro Evaluation of PNA− Peptide− DETA Conjugates as Potential Cell Penetrating Artificial Ribonucleases | |
Zhilina et al. | PNA− Nitrogen Mustard Conjugates Are Effective Suppressors of HER-2/neu and Biological Tools for Recognition of PNA/DNA Interactions | |
ATE520784T1 (de) | Den transmembrantransport von nukleinsäuren fördernde nukleotidsequenzen | |
MXPA04005992A (es) | Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa. | |
Holtet et al. | Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative | |
RU2008153051A (ru) | Способ направленной доставки днк в опухолевые и стволовые клетки | |
WO2003092736A3 (en) | Peptide nucleic acid conjugates with transporter peptides | |
Wrzesiński et al. | tRNAPhe cleavage by aminoglycosides is triggered off by formation of an abasic site | |
Wang et al. | Inhibition of Heat Shock Transcription Factor Binding by a Linear Polyamide Binding in an Unusual 1: 1 Mode | |
TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |